Veda is derived from the Sanskrit word for the creation of knowledge. With our team of industry leading experts, we operate at the forefront of scientific innovation to push the limits of what’s possible in the field of molecular detection. VedaBio is unlocking a universe of possibilities in molecular biology with a breakthrough platform for near-instant molecular detection of highly multiplexed analytes, delivering best-in-class accuracy without the need for target amplification.
Location: United States
Employees: 11-50
Total raised: $65M
Founded date: 2021
Investors 1
| Date | Name | Website |
| 06.11.2023 | OMX Ventur... | omx.vc |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 24.09.2025 | Series A | $25M | - |
| 17.10.2023 | Series A | $40M | - |
Mentions in press and media 3
| Date | Title | Description |
| 24.09.2025 | VedaBio: Significant Funding Secured And Strategic Partnership Signed Advance Molecular Diagnostics | VedaBio, an innovative biotechnology company dedicated to transforming the landscape of molecular detection, has recently announced a significant extension of its Series A funding. A strategic agreement with Siemens Healthineers, a leading ... |
| 17.10.2023 | VedaBio Launches With Over $40M in Initial Funding | VedaBio, a San Diego, CA-based biotechnology company which specializes in molecular detection, raised over $40M in initial funding. The round was led by OMX Ventures along with a group of family offices, including Kleinmuntz Associates. The... |
| - | VedaBio | “Unlocking the true power of CRISPR for molecular detection. Our platform enables ultra-rapid molecular detection without the need for target amplification.” |